Enveda
The Clinical Development Director at Enveda leads the clinical development of a first-in-class medicine targeting metabolism and autoimmune diseases. This role involves designing the first-in-human program, establishing the clinical development plan, and building a network of key opinion leaders to support early-phase trials. The position requires strategic oversight of translational and biomarker strategies while collaborating with cross-functional teams to advance the asset toward regulatory approval.
Headquarters
Boulder, Colorado, United States
Company Size
201-500 employees
Founded
2019
Enveda is an AI-driven drug discovery company that learns from nature to discover medicines faster than the industry average. Their platform reads and translates nature's hidden chemistry at unprecedented speed and scale, unlocking the chemical potential of the natural world — including billions of years of evolutionary intelligence — for drug hunters. Enveda's mission is to give hope to millions of people worldwide by accelerating the discovery of better, nature-derived medicines.
Enveda harvests another $150M to advance nature-inspired drugs
Sep 4, 2025
Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors
Sep 4, 2025
A drug discovery startup banks $150M for immune and obesity drugs
Sep 4, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Enveda.
54% above the average for this role
With Mother Nature as its lead chemist, Enveda clinches another $150M
Sep 4, 2025
Prin. Scientist, Clinical Research
MSD
Sr. Director – Immunology Translational Medicine
Eli Lilly and Company
Executive Medical Director, Early Clinical Development
Eli Lilly and Company
Principal Scientist
Merck & Co., Inc.
Vice President, Inflammatory and Immune Disease Biomarker Development
Apogee Therapeutics
China Biomarker Lead
Takeda Pharmaceuticals Korea Co., Ltd.